MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fonc.2023.1124730

Медицинская библиотека · Frontiers in oncology · 2023

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer.

Wang Ting, Shao Qianwen, Xiao Chunmei, Liu Lianke

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

Immunotherapy has become a very effective treatment for many cancers. It has a unique set of immune system-related adverse effects, collectively known as immune-related adverse events (irAEs). Skin toxicities are the most common irAEs, of which bullous pemphigoid, although rare, is potentially life-threatening and affects patients' survival. In this article, we report the treatment of bullous pemphigoid caused by programmed cell death protein-1 (PD-1) in a case of proficient mismatch repair (pMMR)/microsatellite stable (MSS) colorectal cancer. No significant adverse effects were observed in the patient after methylprednisone was tapered to 4 mg twice a day. No new skin lesions occurred recently in the patient and the original skin lesions healed. In particular, the patient's immunotherapy was not stopped and the best outcome was a partial remission of the disease, lasting for more than 8 months.

Для цитирования: Wang Ting, Shao Qianwen, Xiao Chunmei, Liu Lianke. Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer.. Frontiers in oncology. 2023. DOI: 10.3389/fonc.2023.1124730.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.